<bill bill-stage="Introduced-in-House" dms-id="HC5DECB181634406C9C48D63A237C62F2" public-private="public" bill-type="olc"> 
<metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 HR 5750 IH: Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2014</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. House of Representatives</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2014-11-20</dc:date>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code> 
<congress>113th CONGRESS</congress>
<session>2d Session</session>
<legis-num>H. R. 5750</legis-num> 
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber> 
<action> 
<action-date date="20141120">November 20, 2014</action-date> 
<action-desc>
        <sponsor name-id="B001257">Mr. Bilirakis</sponsor> (for himself, <cosponsor name-id="B001251">Mr. Butterfield</cosponsor>, <cosponsor name-id="M001157">Mr. McCaul</cosponsor>, and <cosponsor name-id="H000324">Mr. Hastings of Florida</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>
      </action-desc>
</action> 
<legis-type>A BILL</legis-type> 
<official-title>To amend the Federal Food, Drug, and Cosmetic Act to authorize a 6-month extension of certain exclusivity periods in the case of approved drugs that are subsequently approved for a new indication to prevent, diagnose, or treat a rare disease or condition, and for other purposes.</official-title> 
</form> 
<legis-body id="HFAF6C76D51664237AA6D35EC8E4A6C1B" style="OLC"> 
<section id="H1634C085364249C5A2256EA3F1330AA5" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the <quote>
          <short-title>
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2014" proposed="true">Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2014</cato:entity-ref>
          </short-title>
        </quote>.</text>
    </section> 
<section id="H3BE316C9233F40C08138A1C18D07B72C">
      <enum>2.</enum>
      <header>Extension of exclusivity periods for a drug approved for a new indication for a rare disease or condition</header> 
<subsection id="HD74E8C4517854C30AB86855F2AC5BD6A">
        <enum>(a)</enum>
        <header>In general</header>
        <text display-inline="yes-display-inline">
          <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:V">Chapter V of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> is amended by inserting after <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505E">section 505E of such Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/355f">
            <cato:entity-ref entity-type="uscode" value="usc/21/355f">21 U.S.C. 355f</cato:entity-ref>
          </external-xref>)</cato:entity> the following:</text> 
<quoted-block style="OLC" id="H96006B1DCB094C3CAD77F5C07B645676" display-inline="no-display-inline"> 
<section id="H560BFCBA10564A548BA8392BD950EDD9">
            <enum>505F.</enum>
            <header>Extension of exclusivity periods for a drug approved for a new indication for a rare disease or condition</header> 
<subsection id="H9B57939C43DF41ED9E5C2710676A81D6">
              <enum>(a)</enum>
              <header>Designation</header> 
<paragraph id="H945DC4A2834940BFA08F536BBA2DD8A1">
                <enum>(1)</enum>
                <header>In general</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall designate a drug as a drug approved for a new indication to prevent, diagnose, or treat a rare disease or condition for purposes of granting the extensions under subsection (b) if—</text> 
<subparagraph id="HCF3D73FE3E0843E7AF1578289AFFEE2D" commented="no">
                  <enum>(A)</enum>
                  <text display-inline="yes-display-inline">prior to approval of an application or supplemental application for the new indication, the drug was approved or licensed for marketing under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:c">section 505(c) of this Act</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351/ss:a">section 351(a) of the Public Health Service Act</cato:entity-ref>, but was not so approved or licensed for the new indication;</text>
                </subparagraph> 
<subparagraph id="H4D1E60FB389E4EED83FA4636171890A5">
                  <enum>(B)</enum> 
<clause id="H21B90314A58446199F637E392E981E38" display-inline="yes-display-inline" commented="no">
                    <enum>(i)</enum>
                    <text>the sponsor of the approved or licensed drug files an application or a supplemental application for approval of the new indication for use of the drug to prevent, diagnose, or treat the rare disease or condition; and</text>
                  </clause> 
<clause id="H4753554963CE42E98B8F14CFC23086DD" indent="up1" commented="no">
                    <enum>(ii)</enum>
                    <text>the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> approves the application or supplemental application; and</text>
                  </clause>
                </subparagraph> 
<subparagraph id="HF778FDCF96834108B0F1E8361D87064E">
                  <enum>(C)</enum>
                  <text display-inline="yes-display-inline">the application or supplemental application for the new indication contains the consent of the applicant to notice being given by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> under paragraph (4) respecting the designation of the drug.</text>
                </subparagraph>
              </paragraph> 
<paragraph id="HA1545F50310D491F885843367D930944">
                <enum>(2)</enum>
                <header>Revocation of designation</header>
                <text display-inline="yes-display-inline"/> 
<subparagraph id="H619F6CBDC404440CBFA303CFA7BF687B">
                  <enum>(A)</enum>
                  <header>In general</header>
                  <text>Except as provided in subparagraph (B), a designation under this subsection shall not be revoked for any reason.</text>
                </subparagraph> 
<subparagraph id="H86B745C6360C44F0A1A6A44F3C62C0B8">
                  <enum>(B)</enum>
                  <header>Exception</header>
                  <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may revoke a designation of a drug under paragraph (1) if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> finds that the application or supplemental application resulting in such designation contained an untrue statement of material fact.</text>
                </subparagraph>
              </paragraph> 
<paragraph id="HBDF2609577294A9988CE92C211C8779D">
                <enum>(3)</enum>
                <header>Notification prior to discontinuance of production for solely commercial reasons</header>
                <text>A designation of a drug under paragraph (1) shall be subject to the condition that the sponsor of the drug will notify the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> of any discontinuance of the production of the drug for solely commercial reasons at least one year before such discontinuance.</text>
              </paragraph> 
<paragraph id="H68F31FD47F614CA18808D9A05B7E8E86">
                <enum>(4)</enum>
                <header>Notice to public</header>
                <text>Notice respecting the designation of a drug under paragraph (1) shall be made available to the public.</text>
              </paragraph> </subsection> 
<subsection id="H98F8A413C9FC45E9BB81B0C75EF0B59E">
              <enum>(b)</enum>
              <header>Extension</header>
              <text>If the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> designates a drug as a drug approved for a new indication for a rare disease or condition, as described in subsection (a)(1)—</text> 
<paragraph id="H921BF8C471FE458A859B00119588AE5D">
                <enum>(1)</enum> 
<subparagraph id="H790789A58B3A4632A2B5E25499F2BF1E" display-inline="yes-display-inline">
                  <enum>(A)</enum>
                  <text>the 4-, 5-, and seven and one-half year periods described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:c/p:3/sp:E/cl:ii">subsections (c)(3)(E)(ii)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:F/cl:ii">(j)(5)(F)(ii) of section 505</cato:entity-ref>, the 3-year periods described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:c/p:3/sp:E/cl:iii">clauses (iii)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:c/p:3/sp:E/cl:iv">(iv) of subsection (c)(3)(E)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:F/cl:iii">clauses (iii)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:F/cl:iv">(iv) of subsection (j)(5)(F) of section 505</cato:entity-ref>, and the 7-year period described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:527">section 527</cato:entity-ref>, as applicable, shall be extended by 6 months; or</text>
                </subparagraph> 
<subparagraph id="HDDC56CE0B099413DB5BB8CAB8E783403" indent="up1">
                  <enum>(B)</enum>
                  <text>the 4- and 12-year periods described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351/ss:k/p:7/sp:A">subparagraphs (A)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351/ss:k/p:7/sp:B">(B) of section 351(k)(7) of the Public Health Service Act</cato:entity-ref> and the 7-year period described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:527">section 527</cato:entity-ref>, as applicable, shall be extended by 6 months; and</text>
                </subparagraph>
              </paragraph> 
<paragraph id="H5AAACEBC7F7B4CBCA1176B40967A768E">
                <enum>(2)</enum>
                <text display-inline="yes-display-inline">if, at the time a drug is designated under subsection (a)(1)—</text> 
<subparagraph id="HA397FEBEBA6A40A7BB9D8071F9780CBB">
                  <enum>(A)</enum>
                  <text>the drug is the subject of a listed patent for which a certification has been submitted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:b/p:2/sp:A/cl:ii">subsection (b)(2)(A)(ii)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:2/sp:A/cl:vii/scl:II">(j)(2)(A)(vii)(II) of section 505</cato:entity-ref> or a listed patent for which a certification has been submitted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:b/p:2/sp:A/cl:iii">subsections (b)(2)(A)(iii)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:2/sp:A/cl:vii/scl:III">(j)(2)(A)(vii)(III) of section 505</cato:entity-ref>, the period during which an application may not be approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:c/p:3">section 505(c)(3)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B">section 505(j)(5)(B)</cato:entity-ref> shall be extended by a period of 6 months after the date the patent expires (including any patent extensions); or</text>
                </subparagraph> 
<subparagraph id="H3ECFD1B23FE84F2BBC55D47F025043DB">
                  <enum>(B)</enum>
                  <text>the drug is the subject of a listed patent for which a certification has been submitted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:b/p:2/sp:A/cl:iv">subsection (b)(2)(A)(iv)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:2/sp:A/cl:vii/scl:IV">(j)(2)(A)(vii)(IV) of section 505</cato:entity-ref>, and in the patent infringement litigation resulting from the certification the court determines that the patent is valid and would be infringed, the period during which an application may not be approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:c/p:3">section 505(c)(3)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B">section 505(j)(5)(B)</cato:entity-ref> shall be extended by a period of 6 months after the date the patent expires (including any patent extensions).</text>
                </subparagraph>
              </paragraph>
            </subsection> 
<subsection id="H3BCCF85E90FD43DBB5AD6735A4B823EA">
              <enum>(c)</enum>
              <header>Relation to pediatric and qualified infectious disease product exclusivity</header>
              <text>Any extension under subsection (b) of a period shall be in addition to any extension of the periods under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505A">sections 505A</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505E">505E of this Act</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351/ss:m">section 351(m) of the Public Health Service Act</cato:entity-ref>, as applicable, with respect to the drug. </text>
            </subsection> 
<subsection id="H83964ED1013C4342A9C11156FB1106DD">
              <enum>(d)</enum>
              <header>Limitations</header>
              <text>The extension described in subsection (b) shall not apply if the drug designated under subsection (a)(1) has previously received an extension by operation of subsection (b).</text>
            </subsection> 
<subsection id="H25088E2AA095476683B7EA9055F1A1EB">
              <enum>(e)</enum>
              <header>Regulations</header> 
<paragraph id="HAAB5D3DDD1964111A0F17E88EDED11E1">
                <enum>(1)</enum>
                <header>In general</header>
                <text>Not later than 2 years after the date of enactment of this section, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall adopt final regulations implementing this section.</text>
              </paragraph> 
<paragraph id="HC9F5B83071134D17BE39106FDE3B35B6">
                <enum>(2)</enum>
                <header>Procedure</header>
                <text>In promulgating a regulation implementing this section, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall—</text> 
<subparagraph id="HA0881D1627B74B78AE110312F901898D">
                  <enum>(A)</enum>
                  <text>issue a notice of proposed rulemaking that includes the proposed regulation;</text>
                </subparagraph> 
<subparagraph id="HC46F4F1390E54C168E4D206B37976249">
                  <enum>(B)</enum>
                  <text>provide a period of not less than 60 days for comments on the proposed regulation; and</text>
                </subparagraph> 
<subparagraph id="HB91300A1B0174D668B0A89CAB12988D2">
                  <enum>(C)</enum>
                  <text>publish the final regulation not less than 30 days before the effective date of the regulation.</text>
                </subparagraph>
              </paragraph> 
<paragraph id="H9CDEAE31307D4E1A87F9244258ADFF25">
                <enum>(3)</enum>
                <header>Restrictions</header>
                <text>Notwithstanding any other provision of law, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall promulgate regulations implementing this section only as described in paragraph (2), except that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may issue interim guidance for sponsors seeking to submit an application or supplemental application described in subsection (a) prior to the promulgation of such regulations.</text>
              </paragraph> 
<paragraph id="HC61FABAB76634C358A5C460254A88E81">
                <enum>(4)</enum>
                <header>Designation prior to regulations</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall designate drugs under subsection (a) prior to the promulgation of regulations under this subsection, if such drugs meet the criteria described in subsection (a).</text>
              </paragraph>
            </subsection> 
<subsection id="HA4680B40439F497781894034DA594E8B">
              <enum>(f)</enum>
              <header>Definition</header>
              <text>In this section, the term <term>rare disease or condition</term> has the meaning given to such term in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:526/ss:a/p:2">section 526(a)(2)</cato:entity-ref>.</text>
            </subsection>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
      </subsection> 
<subsection id="HDD3A4A4DA95B434CAF3E66DAD472EFF1">
        <enum>(b)</enum>
        <header>Application</header>
        <text display-inline="yes-display-inline">
          <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505F" proposed="true">Section 505F of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>, as added by subsection (a), applies only with respect to a drug for which an application or supplemental application described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505F/ss:a/p:1/sp:B/cl:i" proposed="true">subsection (a)(1)(B)(i) of such section 505F</cato:entity-ref> is first approved under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:c">section 505(c) of such Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/355">
            <cato:entity-ref entity-type="uscode" value="usc/21/355/c">21 U.S.C. 355(c)</cato:entity-ref>
          </external-xref>)</cato:entity> or <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Public Health Service Act/s:351/ss:a">section 351(a) of the Public Health Service Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/262">
            <cato:entity-ref entity-type="uscode" value="usc/42/262/a">42 U.S.C. 262(a)</cato:entity-ref>
          </external-xref>)</cato:entity> on or after the date of the enactment of this Act.</text>
      </subsection> 
<subsection id="H3AFCFE6B47AA446FB8F6CB658D0E69BA">
        <enum>(c)</enum>
        <header>Conforming amendments</header> 
<paragraph id="H2B5630C5078044A1BE6AC401F824281F">
          <enum>(1)</enum>
          <header>Relation to pediatric exclusivity for drugs</header>
          <text display-inline="yes-display-inline">
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505A">Section 505A of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/355a">
              <cato:entity-ref entity-type="uscode" value="usc/21/355a">21 U.S.C. 355a</cato:entity-ref>
            </external-xref>)</cato:entity> is amended—</text> 
<subparagraph id="H7C3556D77C2A4EB9A74B7E0DAE88E5CA">
            <enum>(A)</enum>
            <text>in subsection (b), by adding at the end the following:</text> 
<quoted-block style="OLC" id="HC0CBAF70C66A4DAFA0110F93F80BE1C2" display-inline="no-display-inline"> 
<paragraph id="H8ED66959EB964C30A49028498944A95C">
                <enum>(3)</enum>
                <header>Relation to exclusivity for a drug approved for a new indication for a rare disease or condition</header>
                <text display-inline="yes-display-inline">Notwithstanding the references in subsection (b)(1) to the lengths of the exclusivity periods after application of pediatric exclusivity, the 6-month extensions described in subsection (b)(1) shall be in addition to any extensions under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505F" proposed="true">section 505F</cato:entity-ref>.</text>
              </paragraph>
              <after-quoted-block>; and</after-quoted-block>
            </quoted-block>
          </subparagraph> 
<subparagraph id="HFEC7D42427C04B8E973F073290984731">
            <enum>(B)</enum>
            <text>in subsection (c), by adding at the end the following:</text> 
<quoted-block style="OLC" id="H57C3892EA8224C568E68D41A7899BB57" display-inline="no-display-inline"> 
<paragraph id="HCDC184EAA3D74432AE074DA4ECB4B07B">
                <enum>(3)</enum>
                <header>Relation to exclusivity for a drug approved for a new indication for a rare disease or condition</header>
                <text display-inline="yes-display-inline">Notwithstanding the references in subsection (c)(1) to the lengths of the exclusivity periods after application of pediatric exclusivity, the 6-month extensions described in subsection (c)(1) shall be in addition to any extensions under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505F" proposed="true">section 505F</cato:entity-ref>.</text>
              </paragraph>
              <after-quoted-block>.</after-quoted-block>
            </quoted-block>
          </subparagraph>
        </paragraph> 
<paragraph id="HB208CD99961E4DAAB736E762EF5A24A7">
          <enum>(2)</enum>
          <header>Relation to exclusivity for new qualified infectious disease products that are drugs</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505E/ss:b">Subsection (b) of section 505E of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/355f">
              <cato:entity-ref entity-type="uscode" value="usc/21/355f">21 U.S.C. 355f</cato:entity-ref>
            </external-xref>)</cato:entity> is amended—</text> 
<subparagraph id="H5879ED8E2BAD40D2BF144C1A731C5038">
            <enum>(A)</enum>
            <text>by amending the subsection heading to read as follows: <quote>
                <header-in-text level="subsection" style="OLC">Relation to pediatric exclusivity and exclusivity for a drug approved for a new indication for a rare disease or condition</header-in-text>
              </quote>; and</text>
          </subparagraph> 
<subparagraph id="H0E02A45D70C04FD7B0835795717D17AE">
            <enum>(B)</enum>
            <text>by striking <quote>any extension of the period under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505A">section 505A</cato:entity-ref>
              </quote> and inserting <quote>any extension of the periods under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505A">sections 505A</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505F" proposed="true">505F</cato:entity-ref>
              </quote>.</text>
          </subparagraph>
        </paragraph> 
<paragraph id="HDD6A59EB5B864503A0CC521B5412D096">
          <enum>(3)</enum>
          <header>Relation to pediatric exclusivity for biological products</header>
          <text display-inline="yes-display-inline">
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Public Health Service Act/s:351/ss:m">Section 351(m) of the Public Health Service Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/262">
              <cato:entity-ref entity-type="uscode" value="usc/42/262/m">42 U.S.C. 262(m)</cato:entity-ref>
            </external-xref>)</cato:entity> is amended by adding at the end the following:</text> 
<quoted-block style="OLC" id="HA700D9BE31E4491AAE384189187F2AF3" display-inline="no-display-inline"> 
<paragraph id="HA68E8ED74E9044F58FB25B26C650FD94">
              <enum>(5)</enum>
              <header>Relation to exclusivity for a biological product approved for a new indication for a rare disease or condition</header>
              <text display-inline="yes-display-inline">Notwithstanding the references in paragraphs (2)(A), (2)(B), (3)(A), and (3)(B) to the lengths of the exclusivity periods after application of pediatric exclusivity, the 6-month extensions described in such paragraphs shall be in addition to any extensions under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505F" proposed="true">section 505F</cato:entity-ref>.</text>
            </paragraph>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
        </paragraph> </subsection>
    </section> 
</legis-body> 
</bill>